Background: In the present study, we examined the association between HbA1c variability and renal disease progression based on estimated glomerular filtration rate (eGFR) decline in patients with type 2 diabetes mellitus (T2DM) in Singapore. Methods: Glycemic burden and renal function were retrospectively assessed in 1628 patients in 2002-2014. Multivariable logistic regression was used to assess the relationships between HbA1c variability (expressed as HbA1c coefficient of variation [HbA1c-CV] in quartiles), HbA1c intrapersonal mean (HbA1c-IM), and eGFR decline, adjusted for baseline covariates. Results: Among patients with relatively good glycemic control (i.e. HbA1c-IM below the median cohort value [8.0%]), HbA1c-CV Quartile 4 was associated with eGFR decline (odds ratio [OR] 1.88; 95% confidence interval [CI] 1.10-3.25). The OR for HbA1c-CV Quartile 4 was 2.20 (95% CI 1.24-3.89) after additional adjustment for HbA1c-IM. Where HbA1c-IM was above the median cohort value, HbA1c-CV Quartiles 3 and 4 were associated with eGFR decline, with ORs of 2.60 (95% CI 1.48-4.55) and 3.29 (95% CI 1.89-5.76) respectively. After further adjusting for HbA1c-IM, the ORs for Quartiles 3 and 4 were 2.69 (95% CI 1.53-4.74) and 3.51 (95% CI 1.98-6.21), respectively. Conclusions: Variability in HbA1c is strongly and independently associated with eGFR decline in patients with T2DM independent of mean HbA1c. The findings may highlight the importance of sustained stable glycemic control in management of diabetes mellitus.
Introduction
Large clinical trials have demonstrated that poorer glycemic control in the form of sustained elevation in HbA1c confers a risk of microvascular complications in diabetes mellitus (DM). 1, 2 However, it is clear that residual vascular risk exists beyond elevated HbA1c. 3 In recent years, there has been emerging interest in the additional effect of glycemic variability on diabetic complications. Glycemic variability can be referred to as short term (i.e. within-day variability, between-day variability) and long term (i.e. variability in the form of HbA1c excursion). 4 The effect of long-term glycemic variability was initially suggested in 1995 from the Diabetes Control and Complications Trial (DCCT), which found that subjects on an intensive treatment regimen had a lower risk of diabetic complications than those on a conventional regimen, even though they had similar average HbA1c levels. 5 However, it was subsequently reported that within-day glycemic variability did not have additional effects on the risk of diabetic complications. 6 Recently, other studies have found an association between HbA1c variability and development of renal disease progression in both type 1 and type 2 DM (T2DM). [7] [8] [9] [10] [11] HbA1c variability was defined as the change in HbA1c from one clinic visit to the next. Thus, HbA1c variability spans longer than with-day, day-to-day or week-to-week fluctuations in glycemia. 12 Although the underlying mechanism is being debated, possible explanations include oxidative stress related to glycemic excursion, 13 the "metabolic memory" phenomenon, and an association of high HbA1c variability with other adverse cardiovascular risk profiles. 14 Notably, most prior studies assessed the development of microalbuminuria 7, 8, 10 as renal outcome despite its limitation as a biomarker. 15 Others examined the occurrence of incident estimated glomerular filtration rate (eGFR) <60 mL/min per 1.73 m 2 , 10 or as end-stage renal disease (ESRD), 9, 11 as renal outcome. Hitherto, there is a paucity of information on the effect of HbA1c variability on eGFR decline, a clinically meaningful parameter because it informs the need for intensifying treatment in patients with T2DM, the predominant type of DM. According to the 2013 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease, 16 clinically meaningful eGFR decline can be defined as a deterioration in eGFR category, accompanied by a ≥25% deterioration in eGFR from baseline. Furthermore, there is a paucity of information on the magnitude of the effect of HbA1c variability in different patients with and without good glycemic control. The aim of the present study was to assess the association between HbA1c variability and eGFR decline based on eGFR decline in patients with T2DM in Singapore. A secondary aim of the study was to examine the effect of HbA1c variability in patients with different levels of glycemic control.
Methods

Study population
The present study is a retrospective study on patients with T2DM attending the Diabetes Centre at Khoo Teck Puat Hospital (KTPH; Alexandra Health Pte Ltd, Singapore), which is an outpatient one-stop center for the management of DM for patients in the northern region of Singapore. Type 2 diabetes mellitus was diagnosed according to American Diabetes Association criteria. 17 Patients are routinely followed-up at the Diabetes Centre every 3-4 months, and HbA1c, eGFR, and the urinary albumin-to-creatinine ratio (uACR) were measured at multiple time points longitudinally from 2002 to 2014. The median (interquartile range [IQR]) number of measurements was as follows: serum creatinine, 8 (6-14) ; uACR, 4 (2-6); and HbA1c, 8 (6) (7) (8) (9) (10) (11) . Exclusion criteria at baseline included age <21 years, pregnancy, active infectious disease, active cancer and autoimmune disease, involvement of other suspected causes of renal diseases, such as urinary tract infection, polycystic kidney disease, hematuria, or a history of glomerulonephritis. In all, 2963 patients were recruited for the study. Ethics approval was obtained from the National Healthcare Group Domain Specific Review Board in Singapore. All patients who participated provided written informed consent.
Further exclusion criteria were then applied for data analysis: fewer than three measurements of eGFR or three readings of HbA1c, fewer than 2 years follow-up or no measurement of uACR. This left 1628 patients who were included in the analysis.
Data collection
Trained nurses extracted information on demographics from patient case records and collected information on family history and smoking history using a standard questionnaire administered to patients. Information on the duration of diabetes was obtained either from patient case records or standard questionnaires. The nurses also measured blood pressure (BP) using an OMRON (Kyoto, Japan) digital BP monitor in seated patients, and measured body weight and height, which were used to calculate body mass index (BMI). Urinary albumin and low-density lipoprotein cholesterol (LDL-C) were measured at the hospital laboratory accredited by the College of American Pathologists using an immunoturibidimetric assay and an enzymatic colorimetric test, respectively (Roche Cobas c 501; Roche, Mannheim, Germany). Estimated glomerular filtration rate was calculated from age and serum creatinine using the Modification of Diet in Renal Disease (MDRD) formula. 18 Urinary ACR was categorized as normal (<30 mg/g), microalbuminuria (30-300 mg/g) or macroalbuminuria (>300 mg/g). Low-density lipoprotein cholesterol was considered abnormal if LDL-C was ≥2.6 mmol/L. 19 
Serial HbA1c measurements
Values of HbA1c were determined using Tina-quant Hemoglobin A1c Gen.3 (Roche Cobas c 501) at the hospital laboratory. Over a median follow-up period of 5.5 years, there was a median number of HbA1c measurements of 8 (IQR 6-11). An HbA1c-IM value was calculated for each patient as the intra-individual mean. The coefficient of variation of HbA1c (HbA1c-CV) was calculated as the standard deviation in intra-individual HbA1c divided by the HbA1c-IM and expressed as a percentage. 20 The HbA1c-CV was chosen as a normalized measure of HbA1c variability so as to correct for larger standard deviations attributed to higher absolute values of HbA1c. 9, 10 The cohort median was derived from the median value of HbA1c-IMs of all patients. 2 ), coupled with a ≥25% reduction in eGFR from baseline. 16 Patients with improvements in eGFR, the same eGFR category, or a <25% reduction in eGFR from baseline were deemed as having no eGFR decline.
Definition of outcome
Statistical analysis
Categorical data are expressed as number (percentage), whereas continuous data are expressed as the mean AE SD or median values with IQR, as appropriate. Chisquared tests were used to compare patient characteristics between groups for categorical variables. Continuous patient characteristics that were not normally distributed were analyzed by the Mann-Whitney test (two groups) and Kruskal-Wallis test (more than two groups). Logistic regression was performed to examine whether HbA1c-IM and HbA1c-CV quartiles were independently associated with eGFR decline, where the HbA1c-CV quartiles were as follows: Quartile 1: 5.5%; Quartile 2: 8.7%; Quartile 3: 12.8%; Quartile 4: 21.2%. Variables with a skewed distribution (eGFR, number of HbA1c measurements, and HbA1c-IM) were natural log (ln) transformed before logistic regression analysis was performed. Six models were constructed: Models 1, 2, and 3 assessed the effects of HbA1c-IM, HbA1c-CV, and both HbA1c-IM and HbA1c-CV, respectively, on eGFR decline among patients with an HbA1c-IM below the cohort median value; Models 4, 5, and 6 assessed the effects of HbA1c-IM, HbA1c-CV, and both HbA1c-IM and HbA1c-CV, respectively, on eGFR decline among patients with an HbA1c-IM above the cohort median value. The models were adjusted for the following baseline covariates: albuminuria categories, eGFR, duration of diabetes, systolic BP (SBP), LDL-C, age, gender, ethnicity, number of HbA1c readings, and use of renin-angiotensin system (RAS) inhibitors (which included angiotensinconverting enzyme [ACE] inhibitors and angiotensin II receptor blockers [ARBs]) at baseline. No significant interaction terms were found using log likelihood ratio tests. Statistical significance was set at two-tailed P < 0.05. The logistic regression analysis was repeated for Models 1-3 where HbA1c-IM was <7.0% for patients aged ≤65 years and HbA1c-IM was <7.5% for those aged >65 years, as well as for Models 4-6 where HbA1c-IM was ≥7.0% for patients aged ≤65 years and HbA1c-IM was ≥7.5% for those aged >65 years. These cut-offs were based on reference values from the American Diabetes Association guidelines. 19, 21 Statistical analyses were performed using STATA version 13.0 (STATA Corp., College Station, TX, USA). Table 1 shows the baseline characteristics of patients. There was a male preponderance of 57.9%. The majority of patients had DM duration ≥10 years (59.1%), and microalbuminuria or macroalbuminuria (54.4%). Median HbA1c-IM was 8.0% (IQR 7.3%-9.1%) and median HbA1c-CV was 10.5% (IQR 7.3%-15.8%). The median number of HbA1c measurements per patient was 8 (IQR 6-11).
Results
Over a median follow-up of 5.5 years (IQR 4.2--7.0 years), 28.7% of patients exhibited renal disease progression from baseline to last follow-up ("progressors"). The median eGFR slope was −1.2 mL/min per 1.73 m 2 per year (IQR −3.9, 0.9 mL/min per 1.73 m 2 per year).
As indicated in Table 1 , patients who were deemed to be progressors were older, more likely to be Malay, and had a longer duration of DM than those who did not progress ("non-progressors"). A lower proportion of Indians were progressors. The progressors also tended to have higher baseline SBP, higher LDL-C, lower baseline eGFR, microalbuminuria, macroalbuminuria, and to be using RAS inhibitor(s) compared with nonprogressors (P < 0.05 for all). The median HbA1c-CV was significantly higher in progressors than nonprogressors (13.5% vs 9.6%, respectively; P < 0.001). Although progressors had a marginally higher HbA1c-IM than non-progressors, the difference was not statistically significant (P = 0.098).
Patient characteristics for different HbA1c-CV quartiles are given in Table 2 . Patients with higher HbA1c variability were more likely to have longer DM duration, were less likely to be male, had poorer baseline glycemic control, lower baseline eGFR, a steeper annual decline in eGFR, were more likely to have microalbuminuria and macroalbuminuria, and were more likely to be using RAS inhibitor(s) (P < 0.05 for all). The highest quartile (Quartile 4) of HbA1c-CV had the lowest proportion of Indians (P < 0.001). Table 3 shows the results of multivariable logistic regression with eGFR decline as the outcome. There were both shared and unshared risk factors associated with eGFR decline in patients with HbA1c-intrapersonal mean below and above the median cohort value. The shared risk factors were Quartile 4 of HbA1c-CV, duration of DM ≥15 years, SBP ≥140 mmHg, microalbuminuria, and macroalbuminuria. In patients with an HbA1c-IM below the median cohort value, specific risk factors were age ≥ 65 years, duration of DM 10-15 years, Malay ethnicity, higher baseline eGFR, and a higher number of HbA1c measurements. For patients with an HbA1c-IM above the median cohort, risk factors associated with eGFR decline were Quartile 3 of HbA1c-CV, Indian ethnicity (lower odds), and LDL-C ≥ 2.6 mmol/L. Table 3 and Fig. 1 Missing data is excluded from the percentage computation for all these items. The range of missing data is 0.2%-14.9%. DM, diabetes mellitus; BMI, body mass index; SBP, systolic blood pressure; HbA1c-IM, HbA1c-intrapersonal mean; eGFR, estimated glomerular filtration rate (eGFR); ACR, albumin to creatinine ratio; LCL-C, low-density lipoprotein cholesterol; RAS, renin-angiotensin system. (Table 4) .
As indicated in
Discussion
The present study has shown that sustained glycemic variability (HbA1c-CV) was a significant risk factor associated with eGFR decline, even after adjusting for cardiovascular risk factors and average long-term glycemic control (HbA1c-IM). In contrast, there was no statistically significant association between HbA1c-IM and renal disease progression (P > 0.05) in the adjusted models. These observations were similar even in repeat analysis using lower thresholds of HbA1c-IM according to ADA guidelines. 19, 21 These observations are agreement with several other reports. For example, the Renal Insufficiency and Cardiovascular Events (RIACE) Italian Multicenter Study also found that HbA1c variability was related to macroalbuminuria and albuminuric Stages 3-5 chronic kidney disease (CKD) independent of HbA1c-IM in patients with T2DM, but not HbA1c-IM per se. 22 In the Tsukuba Kawai Diabetes Registry study involving patients with T2DM, HbA1c variability was reported to affect the development of microalbuminuria to the same extent as HbA1c-IM. 8 That said, we do not propose to ignore serial HbA1c measurements at regular intervals as the standard of care in diabetes management in view of the ongoing debate on the use of HbA1c variability as a marker of diabetes complications and the absence of randomized control trials to specifically address HbA1c variability as a therapeutic Models 1 and 4 assessed the effects of natural log (ln)-transformed HbA1c intrapersonal mean (IM) on eGFR decline. Models 2 and 5 assessed the effects of HbA1c coefficient of variation (HbA1c-CV) quartiles on eGFR decline. Models 3 and 6 assessed the effects of ln-transformed HbA1c-IM and HbA1c-CV quartiles on eGFR decline. All models were adjusted for age at entry, gender, duration of diabetes mellitus (DM), ethnicity, systolic blood pressure (SBP) ≥140 mmHg, lntransformed baseline eGFR, albumin to creatinine ratio (ACR) group, low-density lipoprotein cholesterol (LDL-C) ≥2.6 mmol/L, ln-transformed number of HbA1c measurements, and the use of renin-angiotensin system (RAS) inhibitor(s). OR, odds ratio; CI, confidence interval. 
Figure 1
Odds ratio of HbA1c variability (HbA1c-CV; in quartiles) in multivariable logistic regression Models 3 and 6 on estimated glomerular filtration rate decline. The HbA1c-CV quartiles were as follows: Q1: 5.5%; Q2: 8.7%; Q3: 12.8%; Q4: 21.2%. target. 3, 23 Nevertheless, the findings of the present study highlight the potential deleterious effects of long-term unstable glycemic control in the development of diabetic complications. It is interesting to note that interventions (e.g. α 1 -glucosidase inhibitor or sodium-glucose cotransporter 2 (SGLT2) inhibitors) that ameliorate glycemic variability favorably (i.e. targeting prandial glycemic excursions with relatively low risk of hypoglycemia) have been found to reduce cardiovascular disease compared with therapeutics less friendly to glycemic variability. [24] [25] [26] However, proof of attenuating glycemic variability to prevent renal progression will require future large-scale clinical trials dedicated to this purpose.
There is on-going debate as to the mechanisms underlying renal injury associated with long-term glycemic variability. One possible explanation is the role of oxidative stress related to glycemic excursions 13 through various pathways, including polyol activity, hexosamine activity, activation of protein kinase C, and generation of advanced glycation end-products (AGEs). 27 Another possibility is the "metabolic memory" phenomenon, whereby regular exposure to suboptimal glycemic control (albeit non-sustained) confers some legacy metabolic burden, which could lead to diabetic nephropathy even after glycemic control improves. 14, 28 An additional possible explanation is the association of high HbA1c variability with other adverse risk profiles, such as unhealthy lifestyle (smoking), elevated blood pressure, peripheral neuropathy, and peripheral vascular disease.
14 That is, variability in HbA1c is perhaps a proxy of exposure to other unfavorable factors, both biological (e.g. comorbidities) and non-biological (unhealthy lifestyle and non-adherence to diabetes management).
The relationship between HbA1c-CV and renal disease progression in the present study may be attributed, in part, to the fact that patients in higher quartiles of HbA1c-CV were more likely to have a more adverse risk profile in terms of mean glycemic control, baseline renal function, and baseline uACR compared with those in lower quartiles of HbA1c-CV. However, after adjustment for these factors, the association between HbA1c-CV and renal disease progression remained significant, indicating that the association is not entirely driven by cardiovascular risk factors or renal status at baseline.
To date, the causes of HbA1c variability have not been extensively investigated. One possible cause of HbA1c variability is non-adherence to diabetic medications, although one study did not find a significant association between visit-to-visit HbA1c variability and non-adherence. 29 We also cannot exclude the possibility that variability in glycemic control is a consequence of renal disease progression, especially with severe or endstage renal failure. Further studies should be done to investigate the causes. Models 1 and 4 assessed the effects of natural log (ln)-transformed HbA1c-mean on eGFR decline. Models 2 and 5 assessed the effects of HbA1c coefficient of variation (HbA1c-CV) quartiles on eGFR decline. Models 3 and 6 assessed the effects of ln-transformed HbA1c-mean and HbA1c-CV quartiles on eGFR decline. All models were adjusted for age at entry, gender, duration of diabetes mellitus (DM), ethnicity, systolic blood pressure (SBP) ≥140 mmHg, lntransformed baseline eGFR, albumin to creatinine ratio (ACR) group, low-density lipoprotein cholesterol (LDL-C) ≥2.6 mmol/L, ln-transformed number of HbA1c measurements, and the use of RAS inhibitor(s). *Cohort median value of all HbA1c-intraindividual means of patients (i.e. 8.0% in Table 3 , and 7.0% for those aged ≤65 years and 7.5% for aged >65 years in Table 4 ). OR, odds ratio; CI, confidence interval.
Another key observation in the present study was that HbA1c-CV was independently associated with renal disease progression even when HbA1c-IM was either above or below the cohort median value (8.0%). Furthermore, Quartile 4 of HbA1c-CV was independently associated with renal disease progression for patients with HbA1c-IM below the cohort median value, whereas both Quartiles 3 and 4 were independently associated with renal disease progression for patients with HbA1c-IM above the cohort median value. This suggests that patients with suboptimal average glycemic control are more susceptible to renal disease progression at a lower magnitude of HbA1c variability than those with better average glycemic control. This is an interesting finding that highlights the importance of achieving consistently good and stable glycemic control. Regular monitoring of HbA1c is therefore fundamental to managing DM and preventing renal complications. Intervention strategies that moderate glycemic variability may add to the benefit derived from achieving a specific HbA1c target.
Most of the risk factors found associated with eGFR decline in the present study were consistent with the literature on the progression of kidney disease. 30 However, there were two unique observations that are worth mentioning. First, patients of Malay ethnicity were more likely to experience eGFR decline, whereas those of Indian ethnicity had lower odds of eGFR decline. This observation supports an earlier finding that Malays have a higher risk of progression to ESRD compared with Chinese and Indians. 31 Subgroup analysis in the present study by ethnic group revealed that Malays had a more adverse risk profile at baseline in terms of SBP, HbA1c-IM, HbA1c-CV, eGFR, uACR, and LDL-C compared with Chinese and Indians (P < 0.001). Conversely, Indians had lower SBP, uACR, and higher eGFR at baseline than Chinese and Indians (P < 0.001). There may be other factors that were not explored in the present study, such as socioeconomic and behavioral factors, that account for the ethnic disparity. The second interesting observation was the association between higher baseline eGFR and eGFR decline in patients with HbA1c-IM below the median cohort value. This may be in line with earlier findings that hyperfiltration is associated with rapid eGFR decline. [32] [33] [34] Further research will be needed to understand the mechanism.
The strengths of the present study include using serial eGFR to construct its trajectory as the "end point" (i.e. renal disease progression), the fairly large multiethnic population studied, the long follow-up duration, completeness of data, comprehensive range of renal status from low risk to very high risk CKD according to KDIGO, and subgroup analysis that adds to the robustness of findings.
The present study also has some limitations. First, we cannot exclude the possibility of reverse causation because progressive CKD globally affects different aspects of diabetes, including β-cell toxicity, the pharmacokinetics and pharmacodynamics of therapeutics, and appetite. 35 For example, renal elimination of insulin may be reduced as eGFR decreases, and hepatic elimination of insulin may be reduced in uremia. Poorer renal function may also contribute to a reduction in gluconeogenesis, which, coupled with uremic malnutrition, inadequate catecholamine discharge, and deficient breakdown and elimination of insulin via the kidney, may potentiate the occurrence of hypoglycemic episodes. 36 Furthermore, in view of longer DM duration among patients with higher HbA1c variability, it is plausible that β-cell exhaustion may contribute to the glycemic instability. This may be related to various potential pathways where excessive products of glucose metabolism may lead to β-cell injury through long-term oxidative stress. 37 Second, there may be concerns about the accuracy of using the MDRD formula to calculate eGFR. However, a previous study demonstrated that the Chronic Kidney Disease Epidemiology (CKD-EPI ) Collaboration equation did not perform better than the MDRD formula in patients with diabetes. 38 Furthermore, earlier studies used the MDRD formula to calculate eGFR when assessing kidney disease progression. 39, 40 Another limitation of the present study was that it was conducted in a real-world clinical care setting where participants received routine medical care and hence there were no prespecified intervals between HbA1c measurements. However, the observations reported herein are relevant to real-life clinical practice. Nevertheless, the number of HbA1c measurements per patient was adjusted for in the analysis. Furthermore, the study participants came from a single DM center in a hospital. As such, the findings cannot be generalized to the general population with diabetes. Third, the data did not shed light on the reasons for HbA1c variability. Therefore, the study cannot reveal any specific intervention strategies that may ameliorate this variability. Finally, we did not collect information on diet and family history, which may explain, in part, ethnic disparities and mechanisms between sustained glycemic variability and progression of renal disease.
Long-term HbA1c variability is strongly associated with renal disease progression in Asian patients with DM, independent of mean HbA1c. The deleterious effects of HbA1c variability are observed among individuals with and without good overall glycemic control.
